List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11823747/publications.pdf Version: 2024-02-01

		729	1066
240	95,482	120	233
papers	citations	h-index	g-index
252	252	252	82223
all docs	docs citations	times ranked	citing authors

TVIEDLACKS

#	Article	IF	CITATIONS
1	MicroRNA expression profiles classify human cancers. Nature, 2005, 435, 834-838.	13.7	8,931
2	Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature, 2009, 458, 223-227.	13.7	3,801
3	A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell, 1992, 71, 587-597.	13.5	3,006
4	p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 1993, 74, 957-967.	13.5	2,848
5	p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature, 1993, 362, 847-849.	13.7	2,829
6	Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature, 2009, 462, 108-112.	13.7	2,707
7	Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature, 1996, 379, 88-91.	13.7	2,223
8	Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell, 2003, 4, 437-450.	7.7	2,150
9	Identification of Bronchioalveolar Stem Cells in Normal Lung and Lung Cancer. Cell, 2005, 121, 823-835.	13.5	2,023
10	A Large Intergenic Noncoding RNA Induced by p53 Mediates Global Gene Repression in the p53 Response. Cell, 2010, 142, 409-419.	13.5	1,919
11	Tumor spectrum analysis in p53-mutant mice. Current Biology, 1994, 4, 1-7.	1.8	1,903
12	Effects of an Rb mutation in the mouse. Nature, 1992, 359, 295-300.	13.7	1,730
13	Sunburn and p53 in the onset of skin cancer. Nature, 1994, 372, 773-776.	13.7	1,724
14	Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes and Development, 2001, 15, 3243-3248.	2.7	1,663
15	Restoration of p53 function leads to tumour regression in vivo. Nature, 2007, 445, 661-665.	13.7	1,662
16	Targeted Deletion Reveals Essential and Overlapping Functions of the miR-17â^¼92 Family of miRNA Clusters. Cell, 2008, 132, 875-886.	13.5	1,504
17	Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nature Genetics, 2007, 39, 673-677.	9.4	1,351
18	Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell, 1992, 70, 923-935.	13.5	1,345

#	Article	IF	CITATIONS
19	Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature, 1995, 377, 552-557.	13.7	1,218
20	Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome. Cell, 2004, 119, 847-860.	13.5	1,140
21	Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature, 2001, 410, 1111-1116.	13.7	1,060
22	Characterization of ribosomal frameshifting in HIV-1 gag-pol expression. Nature, 1988, 331, 280-283.	13.7	928
23	p53-Dependent apoptosis suppresses tumor growth and progression in vivo. Cell, 1994, 78, 703-711.	13.5	873
24	MicroRNAs and Cancer: Short RNAs Go a Long Way. Cell, 2009, 136, 586-591.	13.5	824
25	Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nature Biotechnology, 2014, 32, 551-553.	9.4	823
26	Suppression of non-small cell lung tumor development by the <i>let-7</i> microRNA family. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 3903-3908.	3.3	808
27	Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nature Medicine, 2005, 11, 63-70.	15.2	785
28	p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature, 2002, 416, 560-564.	13.7	775
29	Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nature Genetics, 1994, 7, 353-361.	9.4	731
30	Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nature Protocols, 2009, 4, 1064-1072.	5.5	711
31	Endogenous oncogenic K-rasG12D stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell, 2004, 5, 375-387.	7.7	710
32	CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature, 2014, 514, 380-384.	13.7	673
33	Tumor Induction and Tissue Atrophy in Mice Lacking E2F-1. Cell, 1996, 85, 537-548.	13.5	671
34	Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature, 2000, 407, 645-648.	13.7	656
35	Signals for ribosomal frameshifting in the rous sarcoma virus gag-pol region. Cell, 1988, 55, 447-458.	13.5	647
36	STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene, 2001, 20, 5054-5058.	2.6	643

#	Article	IF	CITATIONS
37	p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens. Nature, 1994, 371, 72-74.	13.7	625
38	Environment Impacts the Metabolic Dependencies of Ras-Driven Non-Small Cell Lung Cancer. Cell Metabolism, 2016, 23, 517-528.	7.2	616
39	KRAS and YAP1 Converge to Regulate EMT and Tumor Survival. Cell, 2014, 158, 171-184.	13.5	608
40	Commensal Microbiota Promote Lung Cancer Development via Î ³ δT Cells. Cell, 2019, 176, 998-1013.e16.	13.5	592
41	Cre-lox-regulated conditional RNA interference from transgenes. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 10380-10385.	3.3	575
42	MHC-II neoantigens shape tumour immunity and response to immunotherapy. Nature, 2019, 574, 696-701.	13.7	563
43	Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nature Genetics, 1996, 12, 144-148.	9.4	555
44	NF1 Tumor Suppressor Gene Function. Cell, 2001, 104, 593-604.	13.5	553
45	Targeted disruption of the three Rb-related genes leads to loss of G1 control and immortalization. Genes and Development, 2000, 14, 3037-3050.	2.7	546
46	A subset of p53-deficient embryos exhibit exencephaly. Nature Genetics, 1995, 10, 175-180.	9.4	544
47	Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. Nature, 2002, 415, 526-530.	13.7	541
48	Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis. Genes and Development, 2013, 27, 1447-1461.	2.7	529
49	Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nature Genetics, 2008, 40, 600-608.	9.4	514
50	Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells. Cell, 2009, 137, 821-834.	13.5	510
51	Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature, 2003, 424, 223-228.	13.7	501
52	The Differential Effects of Mutant p53 Alleles on Advanced Murine Lung Cancer. Cancer Research, 2005, 65, 10280-10288.	0.4	488
53	Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma. Nature, 2009, 462, 104-107.	13.7	483
54	Expression of tumour-specific antigens underlies cancer immunoediting. Nature, 2012, 482, 405-409.	13.7	478

#	Article	IF	CITATIONS
55	Characterization of the p53-Dependent Postmitotic Checkpoint following Spindle Disruption. Molecular and Cellular Biology, 1998, 18, 1055-1064.	1.1	466
56	Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. Nature Medicine, 2017, 23, 1362-1368.	15.2	462
57	Tumor predisposition in mice mutant for p63 and p73: Evidence for broader tumor suppressor functions for the p53 family. Cancer Cell, 2005, 7, 363-373.	7.7	455
58	Autophagy Is Required for Glucose Homeostasis and Lung Tumor Maintenance. Cancer Discovery, 2014, 4, 914-927.	7.7	450
59	Tissue of origin dictates branched-chain amino acid metabolism in mutant <i>Kras</i> -driven cancers. Science, 2016, 353, 1161-1165.	6.0	447
60	Mouse Models of Tumor Development in Neurofibromatosis Type 1 . Science, 1999, 286, 2172-2176.	6.0	441
61	PKM2 Isoform-Specific Deletion Reveals a Differential Requirement for Pyruvate Kinase in Tumor Cells. Cell, 2013, 155, 397-409.	13.5	429
62	LincRNA-p21 Activates p21 In cis to Promote Polycomb Target Gene Expression and to Enforce the G1/S Checkpoint. Molecular Cell, 2014, 54, 777-790.	4.5	412
63	An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nature Genetics, 2005, 37, 48-55.	9.4	392
64	<i>Dicer1</i> functions as a haploinsufficient tumor suppressor. Genes and Development, 2009, 23, 2700-2704.	2.7	391
65	<scp>PKM</scp> 2, cancer metabolism, and the road ahead. EMBO Reports, 2016, 17, 1721-1730.	2.0	384
66	Suppression of lung adenocarcinoma progression by Nkx2-1. Nature, 2011, 473, 101-104.	13.7	383
67	Growth-Inhibitory and Tumor- Suppressive Functions of p53 Depend on Its Repression of CD44 Expression. Cell, 2008, 134, 62-73.	13.5	381
68	Cooperative tumorigenic effects of germline mutations in Rb and p53. Nature Genetics, 1994, 7, 480-484.	9.4	379
69	Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nature Genetics, 2000, 26, 109-113.	9.4	379
70	Circadian Rhythm Disruption Promotes Lung Tumorigenesis. Cell Metabolism, 2016, 24, 324-331.	7.2	366
71	The retinoblastoma gene family in differentiation and development. Oncogene, 1999, 18, 7873-7882.	2.6	362
72	Mutation of E2f-1 Suppresses Apoptosis and Inappropriate S Phase Entry and Extends Survival of Rb-Deficient Mouse Embryos. Molecular Cell, 1998, 2, 293-304.	4.5	361

#	Article	IF	CITATIONS
73	Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses. Immunity, 2015, 43, 579-590.	6.6	360
74	Vascular system defects and neuronal apoptosis in mice lacking Ras GTPase-activating protein. Nature, 1995, 377, 695-701.	13.7	357
75	Rapid modelling of cooperating genetic events in cancer through somatic genome editing. Nature, 2014, 516, 428-431.	13.7	353
76	Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Nature Medicine, 2015, 21, 1163-1171.	15.2	349
77	Cancer Modeling in the Modern Era. Cell, 2002, 108, 135-144.	13.5	348
78	Applications of the CRISPR–Cas9 system in cancer biology. Nature Reviews Cancer, 2015, 15, 387-393.	12.8	340
79	A mouse model for the learning and memory deficits associated with neurofibromatosis type I. Nature Genetics, 1997, 15, 281-284.	9.4	336
80	Classification of Proliferative Pulmonary Lesions of the Mouse. Cancer Research, 2004, 64, 2307-2316.	0.4	313
81	The Nf2 Tumor Suppressor, Merlin, Functions in Rac-Dependent Signaling. Developmental Cell, 2001, 1, 63-72.	3.1	311
82	PERP, an apoptosis-associated target of p53, is a novel member of the PMP-22/gas3 family. Genes and Development, 2000, 14, 704-718.	2.7	310
83	Context-Dependent Transformation of Adult Pancreatic Cells by Oncogenic K-Ras. Cancer Cell, 2009, 16, 379-389.	7.7	305
84	Characterizing deformability and surface friction of cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 7580-7585.	3.3	297
85	Taking the Study of Cancer Cell Survival to a New Dimension. Cell, 2002, 111, 923-925.	13.5	279
86	Cell-cycle control and its watchman. Nature, 1996, 381, 643-644.	13.7	278
87	Loss of E2F-1 reduces tumorigenesis and extends the lifespan of Rb1(+/â^') mice. Nature Genetics, 1998, 18, 360-364.	9.4	274
88	A spatially and temporally restricted mouse model of soft tissue sarcoma. Nature Medicine, 2007, 13, 992-997.	15.2	274
89	A Wnt-producing niche drives proliferative potential and progression in lung adenocarcinoma. Nature, 2017, 545, 355-359.	13.7	265
90	A dominant-negative effect drives selection of <i>TP53</i> missense mutations in myeloid malignancies. Science, 2019, 365, 599-604.	6.0	265

TYLER JACKS

#	Article	IF	CITATIONS
91	Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature, 2010, 468, 572-575.	13.7	255
92	In vivo genome editing and organoid transplantation models of colorectal cancer and metastasis. Nature Biotechnology, 2017, 35, 569-576.	9.4	248
93	Genetic and Clonal Dissection of Murine Small Cell Lung Carcinoma Progression by Genome Sequencing. Cell, 2014, 156, 1298-1311.	13.5	241
94	Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. Journal of Clinical Investigation, 2004, 113, 528-538.	3.9	231
95	Merlin, the Product of the Nf2 Tumor Suppressor Gene, Is an Inhibitor of the p21-Activated Kinase, Pak1. Molecular Cell, 2003, 12, 841-849.	4.5	222
96	Nkx2-1 Represses a Latent Gastric Differentiation Program in Lung Adenocarcinoma. Molecular Cell, 2013, 50, 185-199.	4.5	215
97	Merlin Phosphorylation by p21-activated Kinase 2 and Effects of Phosphorylation on Merlin Localization. Journal of Biological Chemistry, 2002, 277, 10394-10399.	1.6	213
98	Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 8773-8778.	3.3	213
99	Small RNA combination therapy for lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E3553-61.	3.3	210
100	Emergence of a High-Plasticity Cell State during Lung Cancer Evolution. Cancer Cell, 2020, 38, 229-246.e13.	7.7	210
101	Endogenous T Cell Responses to Antigens Expressed in Lung Adenocarcinomas Delay Malignant Tumor Progression. Cancer Cell, 2011, 19, 72-85.	7.7	209
102	Cell type-specific effects of Rb deletion in the murine retina. Genes and Development, 2004, 18, 1681-1694.	2.7	208
103	Lung Adenocarcinoma Distally Rewires Hepatic Circadian Homeostasis. Cell, 2016, 165, 896-909.	13.5	195
104	Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 2948-2953.	3.3	176
105	Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes and Development, 2010, 24, 837-852.	2.7	174
106	RhoA-Dependent Phosphorylation and Relocalization of ERM Proteins into Apical Membrane/Actin Protrusions in Fibroblasts. Molecular Biology of the Cell, 1998, 9, 403-419.	0.9	171
107	Notum produced by Paneth cells attenuates regeneration of aged intestinal epithelium. Nature, 2019, 571, 398-402.	13.7	166
108	Suppression of Rev3, the catalytic subunit of Polζ, sensitizes drug-resistant lung tumors to chemotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 20786-20791.	3.3	160

#	Article	IF	CITATIONS
109	Mutational landscape of <i>ECFR-</i> , <i>MYC-</i> , and <i>Kras-</i> driven genetically engineered mouse models of lung adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E6409-E6417.	3.3	158
110	Targeted Deletion Reveals an Essential Function for the Telomere Length Regulator Trf1. Molecular and Cellular Biology, 2003, 23, 6533-6541.	1.1	150
111	Requirement for Rac1 in a K-ras–Induced Lung Cancer in the Mouse. Cancer Research, 2007, 67, 8089-8094.	0.4	148
112	p21 Is a Critical CDK2 Regulator Essential for Proliferation Control in Rb-deficient Cells. Journal of Cell Biology, 1998, 141, 503-514.	2.3	145
113	ROS Fusion Tyrosine Kinase Activates a SH2 Domain–Containing Phosphatase-2/Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Signaling Axis to Form Glioblastoma in Mice. Cancer Research, 2006, 66, 7473-7481.	0.4	145
114	Nuclear factor I/B is an oncogene in small cell lung cancer. Genes and Development, 2011, 25, 1470-1475.	2.7	142
115	Nf1 Regulates Hematopoietic Progenitor Cell Growth and Ras Signaling in Response to Multiple Cytokines. Journal of Experimental Medicine, 1998, 187, 1893-1902.	4.2	140
116	Epigenomic State Transitions Characterize Tumor Progression in Mouse Lung Adenocarcinoma. Cancer Cell, 2020, 38, 212-228.e13.	7.7	140
117	Caspase-2-Mediated Cleavage of Mdm2 Creates a p53-Induced Positive Feedback Loop. Molecular Cell, 2011, 43, 57-71.	4.5	139
118	Use of gene expression profiling to direct in vivo molecular imaging of lung cancer. Proceedings of the United States of America, 2005, 102, 14404-14409.	3.3	133
119	Nf1 and Gmcsf Interact in Myeloid Leukemogenesis. Molecular Cell, 2000, 5, 189-195.	4.5	132
120	Mist1-KrasG12D Knock-In Mice Develop Mixed Differentiation Metastatic Exocrine Pancreatic Carcinoma and Hepatocellular Carcinoma. Cancer Research, 2006, 66, 242-247.	0.4	132
121	Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus. Blood, 2011, 117, 2022-2032.	0.6	132
122	Survival of pancreatic cancer cells lacking KRAS function. Nature Communications, 2017, 8, 1090.	5.8	131
123	Germline loss of PKM2 promotes metabolic distress and hepatocellular carcinoma. Genes and Development, 2016, 30, 1020-1033.	2.7	122
124	Stromal Expression of miR-143/145 Promotes Neoangiogenesis in Lung Cancer Development. Cancer Discovery, 2016, 6, 188-201.	7.7	122
125	Modeling human lung cancer in mice: similarities and shortcomings. Oncogene, 1999, 18, 5318-5324.	2.6	121
126	Mammalian RNAi: a practical guide. BioTechniques, 2005, 39, 215-224.	0.8	121

#	Article	IF	CITATIONS
127	Dynamic regulation of the Ras pathway via proteolysis of the NF1 tumor suppressor. Genes and Development, 2003, 17, 449-454.	2.7	120
128	Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis. Genes and Development, 2007, 21, 694-707.	2.7	120
129	p63 and p73 Transcriptionally Regulate Genes Involved in DNA Repair. PLoS Genetics, 2009, 5, e1000680.	1.5	120
130	The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer. Cancer Cell, 2021, 39, 1342-1360.e14.	7.7	119
131	HIF-2α deletion promotes Kras-driven lung tumor development. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 14182-14187.	3.3	117
132	Spatial genomics enables multi-modal study of clonal heterogeneity in tissues. Nature, 2022, 601, 85-91.	13.7	117
133	Increased Sensitivity to UV Radiation in Mice with a p53 Point Mutation at Ser389. Molecular and Cellular Biology, 2004, 24, 8884-8894.	1.1	116
134	Defective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23. EMBO Journal, 2004, 23, 3689-3699.	3.5	116
135	Response and Resistance to NF-κB Inhibitors in Mouse Models of Lung Adenocarcinoma. Cancer Discovery, 2011, 1, 236-247.	7.7	116
136	Quantitative proteomics identify Tenascin-C as a promoter of lung cancer progression and contributor to a signature prognostic of patient survival. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E5625-E5634.	3.3	116
137	Regulation of the Neurofibromatosis Type 2 Tumor Suppressor Protein, Merlin, by Adhesion and Growth Arrest Stimuli. Journal of Biological Chemistry, 1998, 273, 7757-7764.	1.6	113
138	Insights into cancer from transgenic mouse models. , 1999, 187, 43-60.		113
139	Conventional type I dendritic cells maintain a reservoir of proliferative tumor-antigen specific TCF-1+ CD8+ TÂcells in tumor-draining lymph nodes. Immunity, 2021, 54, 2338-2353.e6.	6.6	111
140	Lineage tracing reveals the phylodynamics, plasticity, and paths of tumor evolution. Cell, 2022, 185, 1905-1923.e25.	13.5	108
141	Double indemnity: p53, BRCA and cancer. Nature Medicine, 1997, 3, 721-722.	15.2	105
142	TUMOR SUPPRESSOR GENE MUTATIONS IN MICE. Annual Review of Genetics, 1996, 30, 603-636.	3.2	104
143	Recapitulation of the Effects of the Human Papillomavirus Type 16 E7 Oncogene on Mouse Epithelium by Somatic Rb Deletion and Detection of pRb-Independent Effects of E7 In Vivo. Molecular and Cellular Biology, 2003, 23, 9094-9103.	1.1	103
144	The Comparative Pathology of Genetically Engineered Mouse Models for Neuroendocrine Carcinomas of the Lung. Journal of Thoracic Oncology, 2015, 10, 553-564.	0.5	100

#	Article	IF	CITATIONS
145	Perp Is a Mediator of p53-Dependent Apoptosis in Diverse Cell Types. Current Biology, 2003, 13, 1985-1990.	1.8	97
146	Activation of the p53-dependent G1 checkpoint response in mouse embryo fibroblasts depends on the specific DNA damage inducer. Oncogene, 2004, 23, 973-980.	2.6	97
147	Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5qâ^' syndrome. Blood, 2011, 118, 4666-4673.	0.6	97
148	Involvement of p53 and p21 in Cellular Defects and Tumorigenesis in Atm â^'/â^' Mice. Molecular and Cellular Biology, 1998, 18, 4385-4390.	1.1	94
149	Requirement of c-Jun NH ₂ -Terminal Kinase for Ras-Initiated Tumor Formation. Molecular and Cellular Biology, 2011, 31, 1565-1576.	1.1	93
150	The Rb tumor suppressor is required for stress erythropoiesis. EMBO Journal, 2004, 23, 4319-4329.	3.5	91
151	An Induced Ets Repressor Complex Regulates Growth Arrest during Terminal Macrophage Differentiation. Cell, 2002, 109, 169-180.	13.5	90
152	Susceptibility to astrocytoma in mice mutant for Nf1 and Trp53 is linked to chromosome 11 and subject to epigenetic effects. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 13008-13013.	3.3	89
153	Identification of DHODH as a therapeutic target in small cell lung cancer. Science Translational Medicine, 2019, 11, .	5.8	89
154	RB signaling prevents replication-dependent DNA double-strand breaks following genotoxic insult. Nucleic Acids Research, 2004, 32, 25-34.	6.5	87
155	Foxa2 and Cdx2 cooperate with Nkx2-1 to inhibit lung adenocarcinoma metastasis. Genes and Development, 2015, 29, 1850-1862.	2.7	87
156	A Reversible Gene-Targeting Strategy Identifies Synthetic Lethal Interactions between MK2 and p53 in the DNA Damage Response InÂVivo. Cell Reports, 2013, 5, 868-877.	2.9	85
157	Antigen dominance hierarchies shape TCF1+ progenitor CD8 TÂcell phenotypes in tumors. Cell, 2021, 184, 4996-5014.e26.	13.5	84
158	p130 Is Dispensable in Peripheral T Lymphocytes: Evidence for Functional Compensation by p107 and pRB. Molecular and Cellular Biology, 1998, 18, 206-220.	1.1	81
159	In Vitro and In Vivo Effects of a Farnesyltransferase Inhibitor onNf1-Deficient Hematopoietic Cells. Blood, 1999, 94, 2469-2476.	0.6	81
160	Technologically advanced cancer modeling in mice. Current Opinion in Genetics and Development, 2002, 12, 105-110.	1.5	77
161	Endocrine-Exocrine Signaling Drives Obesity-Associated Pancreatic Ductal Adenocarcinoma. Cell, 2020, 181, 832-847.e18.	13.5	77
162	Uncoupling Cancer Mutations Reveals Critical Timing of p53 Loss in Sarcomagenesis. Cancer Research, 2011, 71, 4040-4047.	0.4	76

#	Article	IF	CITATIONS
163	Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response. Current Opinion in Immunology, 2013, 25, 192-199.	2.4	76
164	Colonoscopy-based colorectal cancer modeling in mice with CRISPR–Cas9 genome editing and organoid transplantation. Nature Protocols, 2018, 13, 217-234.	5.5	74
165	Chimeric mouse tumor models reveal differences in pathway activation between ERBB family– and KRAS-dependent lung adenocarcinomas. Nature Biotechnology, 2010, 28, 71-78.	9.4	71
166	ARF Is Not Required for Apoptosis in Rb Mutant Mouse Embryos. Current Biology, 2002, 12, 159-163.	1.8	70
167	Cyclooxygenase-1 Is Overexpressed in Multiple Genetically Engineered Mouse Models of Epithelial Ovarian Cancer. Cancer Research, 2006, 66, 2527-2531.	0.4	70
168	Murine bilateral retinoblastoma exhibiting rapid-onset, metastatic progression and N-myc gene amplification. EMBO Journal, 2007, 26, 784-794.	3.5	69
169	A functional switch from lung cancer resistance to susceptibility at the Pas1 locus in Kras2LA2 mice. Nature Genetics, 2006, 38, 926-930.	9.4	67
170	The Related Retinoblastoma (pRb) and p130 Proteins Cooperate to Regulate Homeostasis in the Intestinal Epithelium. Journal of Biological Chemistry, 2006, 281, 638-647.	1.6	66
171	Differential <i>Tks5</i> isoform expression contributes to metastatic invasion of lung adenocarcinoma. Genes and Development, 2013, 27, 1557-1567.	2.7	62
172	Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	62
173	Integrated cistromic and expression analysis of amplified <i>NKX2-1</i> in lung adenocarcinoma identifies <i>LMO3</i> as a functional transcriptional target. Genes and Development, 2013, 27, 197-210.	2.7	61
174	Dissecting cell-type-specific metabolism in pancreatic ductal adenocarcinoma. ELife, 2020, 9, .	2.8	61
175	Dominant Role of Oncogene Dosage and Absence of Tumor Suppressor Activity in <i>Nras-</i> Driven Hematopoietic Transformation. Cancer Discovery, 2013, 3, 993-1001.	7.7	60
176	Mice Expressing a Mammary Gland–Specific R270H Mutation in the p53 Tumor Suppressor Gene Mimic Human Breast Cancer Development. Cancer Research, 2005, 65, 8166-8173.	0.4	59
177	Proliferation and Tumorigenesis of a Murine Sarcoma Cell Line in the Absence of DICER1. Cancer Cell, 2012, 21, 848-855.	7.7	58
178	Clonal dynamics following p53 loss of heterozygosity in Kras-driven cancers. Nature Communications, 2016, 7, 12685.	5.8	58
179	Urinary detection of lung cancer in mice via noninvasive pulmonary protease profiling. Science Translational Medicine, 2020, 12, .	5.8	58
180	Imaging Primary Lung Cancers in Mice to Study Radiation Biology. International Journal of Radiation Oncology Biology Physics, 2010, 76, 973-977.	0.4	57

#	Article	IF	CITATIONS
181	Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer. Nature Cancer, 2021, 2, 1071-1085.	5.7	57
182	Myeloid Malignancies Induced by Alkylating Agents in Nf1 Mice. Blood, 1999, 93, 3617-3623.	0.6	55
183	Tissue-specific p19 ^{Arf} regulation dictates the response to oncogenic K-ras. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 10184-10189.	3.3	54
184	A Modular Assembly Platform for Rapid Generation of DNA Constructs. Scientific Reports, 2016, 6, 16836.	1.6	54
185	CRISPR-mediated modeling and functional validation of candidate tumor suppressor genes in small cell lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 513-521.	3.3	54
186	IL-33 Signaling Alters Regulatory T Cell Diversity in Support of Tumor Development. Cell Reports, 2019, 29, 2998-3008.e8.	2.9	53
187	A versatile reporter system for CRISPR-mediated chromosomal rearrangements. Genome Biology, 2015, 16, 111.	13.9	52
188	A big step in the study of small cell lung cancer. Cancer Cell, 2003, 4, 163-166.	7.7	50
189	Enhanced adaptive immune responses in lung adenocarcinoma through natural killer cell stimulation. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 17460-17469.	3.3	50
190	Rb and N- ras Function Together To Control Differentiation in the Mouse. Molecular and Cellular Biology, 2003, 23, 5256-5268.	1.1	49
191	<i>Smarca4</i> Inactivation Promotes Lineage-Specific Transformation and Early Metastatic Features in the Lung. Cancer Discovery, 2022, 12, 562-585.	7.7	48
192	Regulated Expression of a Tumor-Associated Antigen Reveals Multiple Levels of T-Cell Tolerance in a Mouse Model of Lung Cancer. Cancer Research, 2008, 68, 9459-9468.	0.4	45
193	Keap1 mutation renders lung adenocarcinomas dependent on Slc33a1. Nature Cancer, 2020, 1, 589-602.	5.7	44
194	ARF mutation accelerates pituitary tumor development in Rb+/- mice. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 16865-16870.	3.3	42
195	Cellular transformation by a FERM domain mutant of the Nf2 tumor suppressor gene. Oncogene, 2002, 21, 5990-5997.	2.6	42
196	Comparison of gene expression and DNA copy number changes in a murine model of lung cancer. Genes Chromosomes and Cancer, 2006, 45, 338-348.	1.5	42
197	Discrete signaling pathways participate in RB-dependent responses to chemotherapeutic agents. Oncogene, 2004, 23, 4107-4120.	2.6	41
198	Characterization of pheochromocytomas in a mouse strain with a targeted disruptive mutation of the neurofibromatosis gene Nf1. Endocrine Pathology, 1995, 6, 323-335.	5.2	40

TYLER JACKS

#	Article	IF	CITATIONS
199	Dominant-Negative but not Gain-of-Function Effects of a p53.R270H Mutation in Mouse Epithelium Tissue after DNA Damage. Cancer Research, 2007, 67, 4648-4656.	0.4	40
200	Deciphering the immunopeptidome in vivo reveals new tumour antigens. Nature, 2022, 607, 149-155.	13.7	38
201	Generation of normal lymphocyte populations by Rb-deficient embryonic stem cells. Current Biology, 1993, 3, 405-413.	1.8	37
202	SnapShot: Lung Cancer Models. Cell, 2012, 149, 246-246.e1.	13.5	36
203	<i>Pten</i> -Null Tumors Cohabiting the Same Lung Display Differential AKT Activation and Sensitivity to Dietary Restriction. Cancer Discovery, 2013, 3, 908-921.	7.7	36
204	Lack of p53 Ser389 Phosphorylation Predisposes Mice to Develop 2-Acetylaminofluorene–Induced Bladder Tumors but not Ionizing Radiation–Induced Lymphomas. Cancer Research, 2005, 65, 3610-3616.	0.4	35
205	Adaptive and Reversible Resistance to Kras Inhibition in Pancreatic Cancer Cells. Cancer Research, 2018, 78, 985-1002.	0.4	35
206	Lessons from thep53 mutant mouse. Journal of Cancer Research and Clinical Oncology, 1996, 122, 319-327.	1.2	33
207	BRG1 Loss Predisposes Lung Cancers to Replicative Stress and ATR Dependency. Cancer Research, 2020, 80, 3841-3854.	0.4	32
208	Inducible de novo expression of neoantigens in tumor cells and mice. Nature Biotechnology, 2021, 39, 64-73.	9.4	32
209	Recombinase-based conditional and reversible gene regulation via XTR alleles. Nature Communications, 2015, 6, 8783.	5.8	31
210	Thinking beyond the tumor cell: Nf1 haploinsufficiency in the tumor environment. Cancer Cell, 2002, 1, 408-410.	7.7	30
211	Genetically engineered mouse models of astrocytoma: GEMs in the rough?. Seminars in Cancer Biology, 2001, 11, 177-190.	4.3	28
212	NF-κB Fans the Flames of Lung Carcinogenesis. Cancer Prevention Research, 2010, 3, 403-405.	0.7	27
213	Mechanisms of carcinogenesis and the mutant mouse. Current Opinion in Genetics and Development, 1996, 6, 65-70.	1.5	26
214	Tumor Suppression by a Severely Truncated Species of Retinoblastoma Protein. Molecular and Cellular Biology, 2002, 22, 3103-3110.	1.1	25
215	Defective proliferative responses in B lymphocytes and thymocytes that lack neurofibromin. Molecular Immunology, 2002, 38, 701-708.	1.0	25
216	Live cell tagging tracking and isolation for spatial transcriptomics using photoactivatable cell dyes. Nature Communications, 2021, 12, 4995.	5.8	25

#	Article	IF	CITATIONS
217	Isoform-specific deletion of PKM2 constrains tumor initiation in a mouse model of soft tissue sarcoma. Cancer & Metabolism, 2018, 6, 6.	2.4	24
218	<i>Rlf–Mycl</i> Gene Fusion Drives Tumorigenesis and Metastasis in a Mouse Model of Small Cell Lung Cancer. Cancer Discovery, 2021, 11, 3214-3229.	7.7	24
219	A mouse plasma PeptideAtlas as a resource for disease proteomics. Genome Biology, 2008, 9, R93.	13.9	22
220	Marked Regression of Metastatic Pilocytic Astrocytoma During Treatment With Imatinib Mesylate (STI-571, Gleevec): A Case Report and Laboratory Investigation. Journal of Pediatric Hematology/Oncology, 2003, 25, 644-648.	0.3	21
221	Progressive Genomic Instability in the FVB/KrasLA2 Mouse Model of Lung Cancer. Molecular Cancer Research, 2011, 9, 1339-1345.	1.5	21
222	Future of Early Detection of Lung Cancer: The Role of Mouse Models. Clinical Cancer Research, 2005, 11, 4999s-5003s.	3.2	20
223	Differences in Nanoparticle Uptake in Transplanted and Autochthonous Models of Pancreatic Cancer. Nano Letters, 2018, 18, 2195-2208.	4.5	20
224	Mitochondrial apoptotic priming is a key determinant of cell fate upon p53 restoration. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	20
225	Mutation at p53 serine 389 does not rescue the embryonic lethality in mdm2 or mdm4 null mice. Oncogene, 2004, 23, 7644-7650.	2.6	18
226	Measuring kinetics and metastatic propensity of CTCs by blood exchange between mice. Nature Communications, 2021, 12, 5680.	5.8	18
227	Deletion of p21 cannot substitute for p53 loss in rescue of mdm2 null lethality. Nature Genetics, 1997, 16, 336-337.	9.4	16
228	Dicer loss and recovery induce an oncogenic switch driven by transcriptional activation of the oncofetal Imp1–3 family. Genes and Development, 2017, 31, 674-687.	2.7	16
229	Tumor suppressor mutations in mice: the next generation. Current Opinion in Genetics and Development, 1998, 8, 304-310.	1.5	15
230	Modulation of tumor induction and progression of oncogenic K-ras-positive tumors in the presence of TGF- 1 haploinsufficiency. Carcinogenesis, 2007, 28, 2589-2596.	1.3	11
231	Nf1gene targeting: toward models and mechanisms. Seminars in Cancer Biology, 1996, 7, 291-298.	4.3	10
232	Protocol for single-cell ATAC sequencing using combinatorial indexing in mouse lung adenocarcinoma. STAR Protocols, 2021, 2, 100583.	0.5	9
233	A GATA4-regulated secretory program suppresses tumors through recruitment of cytotoxic CD8 T cells. Nature Communications, 2022, 13, 256.	5.8	8
234	Myeloid Malignancies Induced by Alkylating Agents in Nf1 Mice. Blood, 1999, 93, 3617-3623.	0.6	6

#	Article	IF	CITATIONS
235	Neurofibromatosis Type 1. , 2003, 222, 223-237.		5
236	Genetic Mouse Models of Cancer. , 2015, , 145-154.e2.		5
237	Basic Mouse Methods for Clinician Researchers. , 2017, , 291-312.		2
238	p53 Family Members: p63 and p73. , 2005, , 187-198.		1
239	Roles of microRNAs in cancer and development. , 2007, , 322-337.		0
240	Genetic Mouse Models of Cancer. , 2008, , 129-138.		0